Obesity associated with systemic inflammation induces insulin resistance (IR), with consequent chronic hyperglycemia. A series of reactions are involved in this process, including increased release of proinflammatory cytokines, and activation of c-Jun N-terminal kinase (JNK), nuclear factor-kappa B (NF-κB) and toll-like receptor 4 (TLR4) receptors. Among the therapeutic tools available nowadays, physical exercise (PE) has a known hypoglycemic effect explained by complex molecular mechanisms, including an increase in insulin receptor phosphorylation, in AMP-activated protein kinase (AMPK) activity, in the Ca2+/calmodulindependent protein kinase kinase (CaMKK) pathway, with subsequent activation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), Rac1, TBC1 domain family member 1 and 4 (TBC1D1 and TBC1D4), in addition to a variety of signaling molecules, such as GTPases, Rab and soluble N-ethylmaleimide-sensitive factor attached protein receptor (SNARE) proteins. These pathways promote greater translocation of GLUT4 and consequent glucose uptake by the skeletal muscle. Phosphoinositide-dependent kinase (PDK), atypical protein kinase C (aPKC) and some of its isoforms, such as PKC-iota/lambda also seem to play a fundamental role in the transport of glucose. In this sense, the association between autophagy and exercise has also demonstrated a relevant role in the uptake of muscle glucose. Insulin, in turn, uses a phosphoinositide 3-kinase (PI3K)-dependent mechanism, while exercise signal may be triggered by the release of calcium from the sarcoplasmic reticulum. The objective of this review is to describe the main molecular mechanisms of IR and the relationship between PE and glucose uptake.
Coronary artery disease (CAD) is one of the leading causes of mortality. High
circulating levels of low-density lipoprotein (LDL) in the blood are associated
with cardiovascular mortality, whether through an etiological role or through
its association with the progression of CAD per se. Randomized clinical trials
have shown that, when LDL levels are reduced, cardiovascular risk is also
reduced, which reinforces this association. The first major trial involving a
hypolipidemic agent of the statin family, the Scandinavian Simvastatin Survival
Study (4S), was published in 1994 and found a significant reduction in mortality
in patients at high cardiovascular risk. However, even in subsequent studies
with different statins, a residual risk persisted, and this seems not to have
changed over time; it is speculated that this risk may be due to statin
intolerance. In this scenario, the potential exists for novel hypolipidemic
agents to drive a true revolution in the therapy of dyslipidemia. The recent
discovery of PCSK9 inhibitors (PCSK9i), a class of hypolipidemic monoclonal
antibodies, is extremely promising. PCSK9 inhibition is capable of promoting a
mean LDL reduction of up to 60%, with potential for very significant clinical
repercussions, as every 38 mg/dL reduction in LDL appears to be associated with
a 22% reduction in cardiovascular risk. This review addresses a brief history of
PCSK9i, major trials of these drugs, cardiovascular outcomes, and aspects
related to their efficacy and safety. Finally, the molecular mechanisms and
possible pleiotropic effects of PCSK9i are also discussed.
The novel coronavirus disease (COVID-19) showed increased morbidity and mortality rates and worse prognosis in individuals with underlying chronic diseases, especially cardiovascular disease and its risk factors, such as hypertension, diabetes, and obesity. There is also evidence of possible links among COVID-19, myocardial infarction, and stroke. Emerging evidence suggests a pro-inflammatory milieu and hypercoagulable state in patients with this infection. Despite anticoagulation, a large proportion of patients requiring intensive care may develop life-threatening thrombotic complications. Indeed, the levels of some markers of hemostatic activation, such as D-dimer, are commonly elevated in COVID-19, indicating potential risk of deep vein thrombosis and pulmonary thromboembolism. In this review, we critically examine and discuss aspects of hypercoagulability and inflammation in COVID-19 and the possible benefits of statins in this scenario, with emphasis on their underlying molecular mechanisms. Moreover, we present recommendations on the use of antiviral drugs in combination with statins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.